Genprex, Inc. GNPX
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Genprex, Inc. (GNPX) is a healthcare company listed in the US with a market value of about $2M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -328%.
About Genprex
Genprex is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. It was profitable in 0 of the last 9 years in our data. Its share count rose by 3789% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 | $0 | — | $0 | $0 |
| Net income | -$16M | -$21M | -$31M | -$24M | -$21M | -$18M | -$11M | -$12M | -$3M |
| Free cash flow | — | — | — | -$18M | -$14M | -$14M | -$7M | -$7M | -$2M |
| EPS (diluted) | $-17.40 | $-266.89 | $-1127.73 | $-989.76 | $-839.78 | $-1019.73 | $-1319.65 | $-1799.52 | $-579.84 |
| Net margin | — | — | — | — | — | — | — | — | — |
| ROIC | -154.0% | -1032.5% | -330.8% | -84.5% | -39.6% | -45.9% | -279.1% | -110.0% | -610.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Genprex pay a dividend?
Not currently.
Is Genprex a good stock to buy?
We do not give buy or sell advice. Genprex scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.